Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical data next year.
Sana Biotechnology is focused on changing the possible for patients through engineered cells. Today the U.S. Food and Drug Administration (FDA) has cleared the company’s 'Investigational New Drug' (IND) application to initiate a study of SC291 in patients with multiple B-cell mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.